Johan Erwin Edmond Weerts

USPTO Granted Patents = 9 (Patent Applications = 4)

EPO Patents = 10 (Patent Applications = 12)

Average Co-Inventor Count = 6.1

ph-index = 3

Forward Citations = 50(Granted Patents)

Company Filing History:

4 out of 2,078

Janssen Pharmaceutica Nv

patents

3 out of 34

Aragon Pharmaceuticals, Inc.

patents

2 out of 123

Astex Therapeutics Limited

patents

Years Active: 2008-2021

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11040953 - Process for the preparation of a diarylthiohydantoin compound (2021-06-22),

2. 10723714 - Processes for the preparation of a diarylthiohydantoin compound (2020-07-28),

3. 10316015 - Processes for the preparation of a diarylthiohydantoin compound (2019-06-11),

4. 9850228 - Pyrazolyl quinoxaline kinase inhibitors (2017-12-26),

5. 9464071 - Pyrazolyl quinoxaline kinase inhibitors (2016-10-11),

6. 8759519 - Mono-hydrochloric salts of an inhibitor of histone deacetylase (2014-06-24),

7. 8716282 - Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors (2014-05-06),

8. 8629144 - Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline (2014-01-14),

9. 7317115 - Mandelates salts of substituted tetracyclic tetrahydrofuran derivatives (2008-01-08),

Title: The Innovations of Johan Erwin Edmond Weerts: A Pioneer in Medicinal Chemistry

Introduction: Johan Erwin Edmond Weerts, hailing from Beerse, Belgium, is a distinguished inventor known for his significant contributions to medicinal chemistry. With a total of nine patents to his name, Weerts has focused much of his research on innovative processes that have the potential to revolutionize treatment options for various medical conditions.

Latest Patents: Among his latest achievements is the patent for a "Process for the preparation of a diarylthiohydantoin compound." This process outlines innovative methodologies and intermediates for preparing a specific compound currently under investigation for the treatment of prostate cancer. This groundbreaking research underscores Weerts’ commitment to addressing critical healthcare challenges through scientific innovation.

Career Highlights: Throughout his career, Weerts has been affiliated with prominent companies in the pharmaceutical sector. Notably, he has worked with Janssen Pharmaceutica NV and Aragon Pharmaceuticals, Inc., where he contributed his expertise in developing novel therapeutic compounds. His endeavors have not only advanced his career but have also greatly impacted industry practices in drug development.

Collaborations: Johan Erwin Edmond Weerts collaborated with several talented colleagues during his professional journey. Notable collaborators include Tom Cornelis, Hortense Govaerts, and Carina Leys, all of whom have played vital roles in the success of his research and development projects. Together, they have fostered an environment of innovation and excellence in their respective fields.

Conclusion: Johan Erwin Edmond Weerts exemplifies the spirit of innovation through his dedicated work in the pharmaceutical industry. With nine patents to his credit and his current focus on advanced treatments for prostate cancer, he continues to influence the field of medicinal chemistry. His collaborations and career achievements reveal a strong commitment to improving patient outcomes through innovative research and development.

This text is generated by artificial intelligence and may not be accurate.